H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Eton Pharmaceuticals to $10 from $9 and keeps a Buy rating on the shares post the Q2 beat.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ETON:
- Eton Pharma (NASDAQ:ETON) Soars on Robust Q2 Showing
- Eton Pharmaceuticals Reports Second Quarter 2023 Financial Results
- ETON Earnings this Week: How Will it Perform?
- Eton Pharmaceuticals price target lowered to $9 from $10 at H.C. Wainwright
- Eton Pharma Tanks after FDA Flags Issues in Methanol Poisoning NDA
